Antibody therapy developer Harbour BioMed has completed a series B round backed by China Life and existing investor Legend Capital.

RXQ Compounding, backed by Ohio Innovation Fund, has added $3.6m in series A funding from Advantage Capital to its coffers.

Uniseed and the Australian government-backed MRCF have invested $18.5m in kidney disease drug developer Certa

Prapela will commercialise medical devices for infants administering to fight drug withdrawal and cardiorespiratory problems.

Carlyle Group is investing up to $350m in healthcare provider One Medical through a primary and secondary share deal.

Ascentage Pharma, based on research at University of Michigan, has filed to list in Hong Kong having raised about $235m in funding.